Generic Medicine Info
Bronchopulmonary disease. Severe hepatic impairment. Pregnancy. Concomitant administration with other CNS depressants.
Special Precautions
Patient with CV disease, respiratory disease (e.g. asthma); history of drug abuse or acute alcoholism. Not for use as obstetric anaesthesia. For use as an alternative agent when conventional therapy is unavailable, ineffective, or inappropriate. For short-term use only (as hypnotic or sedative). Avoid abrupt withdrawal. Avoid injecting near nerve trunks; may cause severe and permanent nerve damage. Use glass syringes for administration. Mild to moderate hepatic impairment. Children. Lactation. Patient Counselling Avoid contact with eyes, skin and clothing. This drug may cause drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Evaluate pregnancy status before initiating therapy.
Adverse Reactions
Significant: CNS depression, metabolic acidosis. If prolonged use: Nephrosis, toxic hepatitis, tolerance, psychological and physical dependence. General disorders and administration site conditions: Inj site reaction (e.g. extreme pain, sterile skin abscess, skin sloughing, fat necrosis, muscular irritation, nerve damage [including permanent damage]). Musculoskeletal and connective tissue disorders: Muscle cramps. Nervous system disorders: Dizziness, tremor. Skin and subcutaneous tissue disorders: Rash, diaphoresis.
Potentially Fatal: Corrosive poisoning (administration of decomposed solution).
Drug Interactions
May potentiate CNS depression with other CNS depressants (e.g. barbiturates); avoid concomitant use.
CIMS Class
Anticonvulsants / Anxiolytics / Hypnotics & Sedatives
ATC Classification
N05CC05 - paraldehyde ; Belongs to the class of aldehydes and derivatives. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on paraldehyde from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in